Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more
Tibet Weixinkang Medicine Co Ltd (603676) - Net Assets
Latest net assets as of September 2025: CN¥1.53 Billion CNY
Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has net assets worth CN¥1.53 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.91 Billion) and total liabilities (CN¥382.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.53 Billion |
| % of Total Assets | 79.94% |
| Annual Growth Rate | 16.94% |
| 5-Year Change | 40.91% |
| 10-Year Change | 243.84% |
| Growth Volatility | 23.71 |
Tibet Weixinkang Medicine Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tibet Weixinkang Medicine Co Ltd (2013–2024)
The table below shows the annual net assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.39 Billion | +3.36% |
| 2023-12-31 | CN¥1.34 Billion | +9.81% |
| 2022-12-31 | CN¥1.22 Billion | +14.37% |
| 2021-12-31 | CN¥1.07 Billion | +8.55% |
| 2020-12-31 | CN¥983.21 Million | +5.72% |
| 2019-12-31 | CN¥930.05 Million | +3.61% |
| 2018-12-31 | CN¥897.64 Million | +4.61% |
| 2017-12-31 | CN¥858.04 Million | +86.77% |
| 2016-12-31 | CN¥459.42 Million | +14.02% |
| 2015-12-31 | CN¥402.93 Million | +40.75% |
| 2014-12-31 | CN¥286.28 Million | +15.54% |
| 2013-12-31 | CN¥247.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Weixinkang Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 168.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥536.95 Million | 38.76% |
| Common Stock | CN¥435.16 Million | 31.41% |
| Other Comprehensive Income | CN¥1.36 Million | 0.10% |
| Other Components | CN¥411.97 Million | 29.74% |
| Total Equity | CN¥1.39 Billion | 100.00% |
Tibet Weixinkang Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Archer Ltd.
LSE:0RBA
|
$140.11 Million |
|
McBride plc
PINK:MCBRF
|
$140.13 Million |
|
Saratoga Investama Sedaya
JK:SRTG
|
$140.13 Million |
|
Blumar
SN:BLUMAR
|
$140.13 Million |
|
ARIMA REAL EST.SOC. EO 10
F:3AZ
|
$140.03 Million |
|
FOS.TOUR.GRP EO-0001
F:6T8
|
$139.99 Million |
|
HELLOFRESH UNSP.ADS/025
F:HFG0
|
$139.95 Million |
|
Shenzhen RoadRover Technology Co Ltd
SHE:002813
|
$139.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Weixinkang Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,340,345,675 to 1,385,442,206, a change of 45,096,531 (3.4%).
- Net income of 246,169,202 contributed positively to equity growth.
- Dividend payments of 177,847,820 reduced retained earnings.
- Share repurchases of 29,999,049 reduced equity.
- Other comprehensive income increased equity by 578,556.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥246.17 Million | +17.77% |
| Dividends Paid | CN¥177.85 Million | -12.84% |
| Share Repurchases | CN¥30.00 Million | -2.17% |
| Other Comprehensive Income | CN¥578.56K | +0.04% |
| Other Changes | CN¥6.20 Million | +0.45% |
| Total Change | CN¥- | 3.36% |
Book Value vs Market Value Analysis
This analysis compares Tibet Weixinkang Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.38x to 3.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.29 | CN¥10.84 | x |
| 2014-12-31 | CN¥1.57 | CN¥10.84 | x |
| 2015-12-31 | CN¥2.21 | CN¥10.84 | x |
| 2016-12-31 | CN¥1.28 | CN¥10.84 | x |
| 2017-12-31 | CN¥2.20 | CN¥10.84 | x |
| 2018-12-31 | CN¥2.08 | CN¥10.84 | x |
| 2019-12-31 | CN¥2.20 | CN¥10.84 | x |
| 2020-12-31 | CN¥2.32 | CN¥10.84 | x |
| 2021-12-31 | CN¥2.52 | CN¥10.84 | x |
| 2022-12-31 | CN¥2.84 | CN¥10.84 | x |
| 2023-12-31 | CN¥3.13 | CN¥10.84 | x |
| 2024-12-31 | CN¥3.21 | CN¥10.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Weixinkang Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.77%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.93%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.34x
- Recent ROE (17.77%) is below the historical average (17.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 35.18% | 24.23% | 1.11x | 1.31x | CN¥59.37 Million |
| 2014 | 37.30% | 27.31% | 1.08x | 1.27x | CN¥78.12 Million |
| 2015 | 28.03% | 25.65% | 0.87x | 1.26x | CN¥72.64 Million |
| 2016 | 25.01% | 26.95% | 0.77x | 1.20x | CN¥68.97 Million |
| 2017 | 11.84% | 24.17% | 0.41x | 1.18x | CN¥15.78 Million |
| 2018 | 8.18% | 9.84% | 0.60x | 1.38x | CN¥-16.33 Million |
| 2019 | 5.99% | 7.51% | 0.57x | 1.40x | CN¥-37.33 Million |
| 2020 | 5.94% | 8.16% | 0.53x | 1.38x | CN¥-39.90 Million |
| 2021 | 8.99% | 9.28% | 0.69x | 1.40x | CN¥-10.82 Million |
| 2022 | 14.50% | 12.65% | 0.84x | 1.36x | CN¥54.90 Million |
| 2023 | 15.97% | 16.18% | 0.74x | 1.33x | CN¥79.98 Million |
| 2024 | 17.77% | 18.93% | 0.70x | 1.34x | CN¥107.62 Million |
Industry Comparison
This section compares Tibet Weixinkang Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Weixinkang Medicine Co Ltd (603676) | CN¥1.53 Billion | 35.18% | 0.25x | $140.08 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |